| NCT ID | NCT07135323 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prescient Medicine Holdings, Inc. |
| Condition | Opioid Use Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2024-11-15 |
| Primary Completion | 2031-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2024-11-15 with a primary completion date of 2031-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
Eligibility Criteria
Inclusion Criteria: * ≥18 years of age * Prior to first opioid prescription * Being considered for first oral opioid prescription (4-30 days) * Prescribed AvertD as part of care * Willing and able to complete yearly assessments for 5 years * Signed informed consent Exclusion Criteria: * Planned opioid prescription \<4 or \>30 days * Any condition making participation unsafe or infeasible per investigator judgment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07135323 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07135323 currently recruiting?
Yes, NCT07135323 is actively recruiting participants. Contact the research team at amanda.smith@concentricsresearch.com for enrollment information.
Where is the NCT07135323 trial being conducted?
This trial is being conducted at Indianapolis, United States.
Who is sponsoring the NCT07135323 clinical trial?
NCT07135323 is sponsored by Prescient Medicine Holdings, Inc.. The trial plans to enroll 4,000 participants.